Moreover, AZD 3759, a blood brain barrier permeable EGFR-tyrosine kinase inhibitor (EGFR-TKI), was found to reduce the phosphorylated α-synuclein levels, a pathological biomarker of Parkinson’s Disease [10]. The gene discussed is EGFR; the disease is Parkinson disease.